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Current Use of Aspirin and Antithrombotic Agents in the United
States Among Outpatients With Atherothrombotic Disease (from
the REduction of Atherothrombosis for Continued Health
[REACH] Registry)
Christopher P. Cannon, MDa,*, Karen E. Rhee, MDb, Robert M. Califf, MDc,
William E. Boden, MDd, Alan T. Hirsch, MDe, Mark J. Alberts, MDf, Greg Cable, PhD, MPAg,
Mingyuan Shao, MSh, E. Magnus Ohman, MDi, P. Gabriel Steg, MDj, Kim A. Eagle, MDk, and
Deepak L. Bhatt, MD, MPHl, for the REACH Registry Investigators
Despite its proven efficacy, low cost, and wide availability, aspirin remains underused. We
examined current aspirin use and determined factors that influence its use among outpatients
in the United States (US). The REduction of Atherothrombosis for Continued Health
(REACH) Registry is an international, prospective, longitudinal study of >68,000 outpatients
with established atherothrombosis or >3 atherothrombotic risk factors. The rates of aspirin use
were compared in various patient subgroups. Multivariate logistic regression models were
constructed to determine the factors influencing the baseline use of aspirin and other antithrombotic agents in the US population. Approximately 70% of 25,686 US outpatients were
treated with aspirin, with greater use in the Midwest and among men, whites, and those aged
<65 years. Among aspirin users, 18% took other antiplatelet agents and 6% took oral anticoagulants. Low-dose aspirin (<100 mg/day) was used in approximately 2/3 of aspirin users. Of
patients not taking aspirin, 1/2 were receiving oral anticoagulants or other antiplatelet agents.
However, 15% of patients used no antithrombotic agent at all. Female gender, current smoking,
or having diabetes mellitus were predictors of a lack of antithrombotic use; white race, atrial
fibrillation or vascular disease, the use of other risk-reducing medications, or treatment by a
cardiologist were associated with a greater likelihood of receiving antithrombotic therapy. In
conclusion, approximately 1/4 of US patients with vascular disease are not treated with aspirin
for secondary prevention, and 15% are not treated with any antithrombotic agent. © 2010
Elsevier Inc. All rights reserved. (Am J Cardiol 2010;105:445– 452)
Aspirin irreversibly inhibits the synthesis of thromboxane A2, a potent vasoconstrictor and platelet pro-aggregant.
Several trials have shown that aspirin doses of 75 to 150 mg
a
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will yield a reduction in cardiovascular events similar to that
realized with higher doses of 150 to 325 mg/day.1 In addition, the risk of major bleeding appears to be lower with
lower aspirin doses.2 Current guidelines recommend 75 to
162 mg/day for secondary prevention of atherosclerotic
vascular disease.3 No prospective registry data are available
describing aspirin use among outpatients with, or at risk of,
clinically manifest atherothrombotic disease in a “realworld” setting. The REduction of Atherothrombosis for
Continued Health (REACH) Registry, an international, prospective, observational study, was designed to collect data
on an ethnically and geographically diverse population
across 44 countries in an outpatient setting. The baseline
characteristics and 1-year outcomes of the global REACH
Registry population have been published previously.4,5 The
primary objectives of the present analysis were to (1) describe the use of aspirin, including the rates of use and
dosage, among patients enrolled in the United States (US)
and (2) identify the independent predictors of aspirin use or
nonuse in the US.
Methods
The REACH Registry is an international, prospective,
longitudinal study of ⬎68,000 patients across 6 continents
recruited from December 2003 to June 2004.4 – 6 The present
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Figure 1. Baseline prevalence of aspirin and other antithrombotic agent use among US patients enrolled in the REACH Registry.

Figure 2. Baseline prevalence of aspirin and other antithrombotic agent use among US patients enrolled in the REACH Registry who were symptomatic or
asymptomatic (with ⱖ3 risk factors only).

report was based on a database lock of July 2006. The
methods have been described previously.6 In brief, the patients were eligible for enrollment if they were aged ⱖ45
years and had ⱖ1 of the following: (1) ⱖ3 atherothrombotic
risk factors; (2) documented coronary artery disease (CAD);
(3) documented cerebrovascular disease; or (4) documented
peripheral artery disease (PAD). The exclusion criteria included patients who were already participating in other
clinical trials, currently hospitalized patients, and those expected to have difficulty returning for follow-up visits. This
protocol was submitted to the institutional review board in
each country according to the local requirements, and all
patients provided signed informed consent. All data were
collected locally using a standard subject data form and
forwarded to a central site. The data control audits were
performed throughout the data collection period by way of
site visits conducted at 10% of all sites that enrolled ⱖ1
patient (6% selected randomly, 4% selected according to
performance level). All case report forms at the audited sites
were monitored for documentation and accuracy.
The aspirin dosage at baseline was evaluated overall and
in patients grouped by age, gender, race, US Census Region,
patient type (asymptomatic with risk factors, CAD at baseline, cerebrovascular disease at baseline, PAD at baseline),
previous revascularization, previous coronary angioplasty/
stenting, and previous coronary artery bypass grafting without previous revascularization. We also evaluated the dif-

ferent combinations of antiplatelet therapy (eg, clopidogrel,
ticlopidine) or oral anticoagulant agents used. Data for aspirin users were represented with and without the missing
data points for the dosages used. The present report was
prepared in compliance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
checklist.7
Descriptive values were calculated using the mean, standard deviation (SD), and range for continuous data and
counts and/or percentages for categorical data. Bivariate
values were also reported as counts and percentages. Multivariate models of the baseline study end points were constructed using the available baseline variables, consisting of
patient level data (medical history, risk factors, sociodemographics, and geographic location) and physician data (specialty, years in practice, and geographic location). Contingency tables, simple Poisson and logistic regression
models, and graphics were used to assess the magnitude,
direction, and functional form of the bivariate relationships between the baseline factors and the study end
points of interest. The method of generalized estimating
equations was then used to construct multivariate hierarchical Poisson or logistic regression models, as appropriate, given the event proportions and evidence-supporting,
technique-specific assumptions. The US Census Region in
which the patient resided was used as a nested level in the
hierarchical models, and several correlation structures were
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Table 1
Baseline characteristics of United States (US) patients enrolled in the REduction of Atherothrombosis for Continued Health Registry (REACH)
according to use of aspirin and other antithrombotic agents
Variable

Aspirin Users
(n ⫽ 18,101)

Concomitant
Antithrombotic
Medication

None
(n ⫽ 12,612)

Other
Antiplatelet
Agents Only
(n ⫽ 3,265)

Age (years)
Age group
⬍65 years
ⱖ65 years
Gender
Male
Female
Race
White
African-American
Hispanic
Asian
Atrial fibrillation
Diabetes
Current smoking
ⱖ1 Antihypertensive
agent
ⱖ1 Lipid-lowering
agent
ⱖ1 Antidiabetic agent
Risk factors only
Symptomatic
CVD
CAD
PAD
Previous
revascularization
Angio/stent only
CABG only
Both
None
Region
Northeast*
Midwest†
South‡
West§

69.8 ⫾ 10.2

68.8 ⫾ 10.6

3,913 (31.2%)
8,629 (68.8%)

Aspirin Nonusers
(n ⫽ 7,512)

Oral
Both Agents
Anticoagulants (n ⫽ 189)
Only
(n ⫽ 1,103)

None
(n ⫽ 3,795)

Other
Antiplatelet
Agents Only
(n ⫽ 11,70)
71.1 ⫾ 10.3

70.8 ⫾ 9.9

70.1 ⫾ 10.5

69.4 ⫾ 10.7

1,179 (36.3%)
2,069 (63.7%)

298 (27.2%)
799 (72.8%)

56 (29.9%)
131 (70.1%)

1,239 (32.8%)
2,542 (67.2%)

7,494 (59.5%)
5,105 (40.5%)

1,940 (59.5%)
1,321 (40.5%)

749 (68.0%)
353 (32.0%)

118 (62.4%)
71 (37.6%)

10,201 (81.7%)
1,215 (9.7%)
660 (5.3%)
339 (2.7%)
710 (5.7%)
6,344 (50.6%)
1,760 (14.3%)
11,818 (93.8%)

2,580 (80.0%)
343 (10.6%)
190 (5.9%)
101 (3.1%)
240 (7.5%)
1,456 (44.8%)
457 (14.4%)
3,093 (94.8%)

942 (86.2%)
93 (8.5%)
37 (3.4%)
16 (1.5%)
480 (44.4%)
521 (47.5%)
97 (8.9%)
1,062 (96.4%)

10,823 (86.0%)

2,876 (88.4%)

5,852 (46.5%)
3,346 (26.7%)
9,178 (73.3%)
1,890 (15.2%)
7,798 (62.3%)
975 (7.7%)

Oral
Both Agents
Anticoagulants (n ⫽ 204)
Only
(n ⫽ 2,026)
73.3 ⫾ 9.6

70.5 ⫾ 10.5

325 (27.9%)
838 (72.1%)

383 (18.9%)
1,640 (81.1%)

61 (30.0%)
142 (70.0%)

1,743 (45.9%)
2,051 (54.1%)

588 (50.3%)
581 (49.7%)

1,155 (57.0%)
871 (43.0%)

110 (53.9%)
94 (46.1%)

160 (84.7%)
14 (7.4%)
10 (5.3%)
3 (1.6%)
69 (38.1%)
92 (48.9%)
21 (11.4%)
182 (96.3%)

2,771 (73.7%)
534 (14.2%)
277 (7.4%)
145 (3.9%)
181 (4.9%)
2,377 (63.0%)
666 (18.1%)
3,490 (92.2%)

857 (74.1%)
179 (15.5%)
68 (5.9%)
46 (4.0%)
66 (5.8%)
580 (49.8%)
167 (14.8%)
1,090 (93.2%)

1,743 (87.0%)
157 (7.8%)
60 (3.0%)
28 (1.4%)
1,061 (53.1%)
936 (46.6%)
213 (10.9%)
1,926 (95.1%)

171 (84.2%)
18 (8.9%)
10 (4.9%)
3 (1.5%)
93 (46.3%)
97 (47.8%)
25 (12.4%)
191 (93.6%)

916 (83.9%)

172 (91.5%)

2,961 (78.3%)

929 (79.6%)

1,506 (74.5%)

173 (85.6%)

1,328 (40.8%)
139 (4.3%)
3,123 (95.7%)
1,097 (34.3%)
2,463 (75.9%)
466 (14.3%)

483 (43.9%)
78 (7.1%)
1,019 (92.9%)
346 (32.2%)
845 (77.3%)
133 (12.1%)

83 (44.4%)
7 (3.7%)
182 (96.3%)
61 (32.6%)
157 (83.5%)
31 (16.4%)

2,217 (58.7%)
2,098 (56.1%)
1,641 (43.9%)
439 (11.8%)
1,253 (33.6%)
236 (6.2%)

524 (44.9%)
120 (10.4%)
1,038 (89.6%)
499 (43.5%)
665 (57.5%)
177 (15.1%)

825 (40.8%)
279 (13.9%)
1,729 (86.1%)
758 (37.9%)
1,244 (62.2%)
203 (10.0%)

90 (44.1%)
16 (7.9%)
187 (92.1%)
92 (45.8%)
140 (69.3%)
42 (20.6%)

2,307 (18.5%)
2,555 (20.5%)
1,035 (8.3%)
6,576 (52.4%)

1,099 (34.2%)
467 (14.5%)
503 (15.7%)
1,144 (35.3%)

226 (20.9%)
259 (23.9%)
183 (16.9%)
415 (37.9%)

61 (33.3%)
24 (13.1%)
53 (29.0%)
45 (24.3%)

287 (7.7%)
302 (8.1%)
120 (3.2%)
3,038 (80.7%)

232 (20.1%)
149 (12.9%)
107 (9.2%)
669 (57.5%)

245 (12.3%)
433 (21.7%)
162 (8.1%)
1,151 (57.4%)

45 (22.2%)
32 (15.8%)
32 (15.8%)
94 (46.1%)

2,418 (19.2%)
3,043 (24.1%)
4,791 (38.0%)
2,231 (17.7%)

528 (16.2%)
940 (28.8%)
1,245 (38.1%)
529 (16.2%)

201 (18.2%)
296 (26.8%)
411 (37.3%)
182 (16.5%)

26 (13.8%)
49 (25.9%)
86 (45.5%)
27 (14.3%)

660 (17.4%)
860 (22.7%)
1,510 (39.8%)
721 (19.0%)

224 (19.1%)
266 (22.7%)
469 (40.1%)
196 (16.8%)

416 (20.5%)
485 (23.9%)
744 (36.7%)
359 (17.7%)

39 (19.1%)
42 (20.6%)
80 (39.2%)
41 (20.1%)

Data are presented as mean ⫾ SD or number (%).
For each variable, percentages reflect total number of patients with available data only, not total number of patients.
* Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey, Pennsylvania.
†
Ohio, Indiana, Illinois, Michigan, Wisconsin, Minnesota, Iowa, Missouri, North Dakota, South Dakota, Nebraska, Kansas.
‡
Delaware, Maryland, District of Columbia, Virginia, West Virginia, North Carolina, South Carolina, Georgia, Florida, Kentucky, Tennessee, Alabama,
Mississippi, Arkansas, Louisiana, Oklahoma, Texas.
§
Montana, Idaho, Wyoming, Colorado, New Mexico, Arizona, Utah, Nevada, Washington, Oregon, California, Alaska, Hawaii.
Angio ⫽ angiography; CABG ⫽ coronary artery bypass grafting; CVD ⫽ cerebrovascular disease.

tested to identify the best fit. The log-likelihood measure,
Akaike Information Criterion, Bayesian information criterion, and Hosmer and Lemeshow’s statistic were used to
assess the various dimensions of model fit. Variance inflation factors, tolerance measures, contingency tables, and
graphic methods were used to assess the degree of collinearity and multicollinearity during the model-building process
and to facilitate model specification. Only subject data with
complete information on model variables were included in

the final models. Fisher’s exact test was used to compare
the categorical variables. No measures were taken to
address the potential nonresponse effects of item-level
missing data. All statistical hypotheses were tested at
␣ ⫽ 0.05. No adjustments were made for multiple comparisons. Odds ratios (ORs) were calculated with their
95% confidence intervals. All statistical calculations
were performed using SAS, version 8.2 (SAS Institute,
Cary, North Carolina).
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Figure 3. Aspirin use by concomitant antithrombotic medication subgroup in the entire US REACH population and doses used among aspirin users. Bar graph
depicts use or lack of aspirin use in the overall population according to concomitant use of other antiplatelet agents and/or oral anticoagulants. Pie charts show
dosage breakdown among aspirin users only, accounting for missing data points.

Results
A total of 25,686 patients were registered in the REACH
database from 1,599 practices in the US. At baseline, 15,360
(59.8%) had CAD, 5,478 (21.3%) had cerebrovascular disease, 2,382 (9.3%) had PAD, and 6,617 (25.8%) were
asymptomatic with risk factors only. Of those with CAD,
11,677 had undergone previous angioplasty/stenting or coronary artery bypass surgery. Of those with cerebrovascular
disease, 792 had previously undergone carotid angioplasty/
stenting or carotid surgery. Of the patients with PAD, 1,558
had a history of lower limb angioplasty/stenting/bypass or
amputation.
At baseline, 71% of patients reported taking aspirin (Figure 1). Of these patients, 70% used aspirin alone, 18% used
aspirin plus other antiplatelet agents, 6% were taking aspirin
and an oral anticoagulant, and 1% were taking all 3 antithrombotic classes. Among patients not receiving aspirin,
1/2 used no antithrombotic agent, 27% took oral anticoagulants, 16% used other antiplatelet agents, and 3% were
taking both another antiplatelet agent and an oral anticoagulant. Predictably, aspirin use was significantly greater
among symptomatic patients than among those with risk
factors only (75% vs 59%; p ⬍0.001; Figure 2). Approximately 15% of patients used no antithrombotic agent at all
(Figure 1). In patients with known disease, 25% were not
taking aspirin, among whom 9.1% were not taking any
antithrombotic. In the asymptomatic group, 34.5% were not
taking antithrombotic medication (Figure 2).
The baseline characteristics of the patients, stratified by
antithrombotic use, are listed in Table 1. Aspirin use was
significantly greater among patients aged ⬍65 years than
those aged ⱖ65 years (73.2% vs 69.5%; p ⬍0.001) and
among men versus women (74.4% vs 65.7%; p ⬍0.001).
Whites had the greatest use of aspirin (71.6%), followed by
Hispanics (68.6%), Asians (68.1%), and African-Americans

(65.5%; p ⫽ 0.017, p ⫽ 0.036, p ⬍0.001, respectively,
compared to whites). The use of aspirin among the US
Census Regions was significantly greater in the Midwest
(72.7%) than in the Northeast (70.9%; p ⫽ 0.039), South
(70.1%; p ⬍0.001), or West (69.3%; p ⬍0.001).
Most patients who reported aspirin use at baseline were
taking a low dose (75 to 100 mg) instead of a higher dose
(ⱖ325 mg). Although the total number of those who reported taking aspirin was 18,101, dosage information was
available for only 16,549 patients, among whom nearly 2/3
used aspirin 75 to 100 mg/day (Figure 3 and Table 2). Only
2% of patients took a “medium” dose (101 to 324 mg).
Patients given the higher dose of aspirin were more often
younger, male, and white (Table 2). More patients with
CAD took high-dose aspirin compared with those with
cerebrovascular disease or PAD (Table 2). Similar to the
overall population of aspirin users, patients taking aspirin
only (without other antithrombotic agents) primarily used
low-dose aspirin (Figure 3). Patients taking aspirin and an
oral anticoagulant, with or without other antiplatelet agents,
more often used low-dose versus high-dose, aspirin (Figure 3).
With nearly 30% of patients not taking aspirin, we
sought to determine which baseline factors were associated
with not using aspirin. The multivariate predictors of not
taking aspirin at baseline are plotted in Figure 4. The strongest predictors were the use of oral anticoagulant agents
(OR 8.32; p ⬍0.0001) or other antiplatelet agents (OR 1.62;
p ⬍0.0001); treatment by an endocrinologist (OR 1.38; p ⫽
0.0002); having diabetes (OR 1.34; p ⬍0.0001), taking
diabetic medication other than insulin or biguanides (OR
1.32; p ⫽ 0.0008), or taking nonsteroidal anti-inflammatory
drugs (OR 1.15; p ⫽ 0.0016); female gender (OR 1.37;
p ⬍0.0001); current smoking (OR 1.19; p ⫽ 0.0004); and
having congestive heart failure (OR 1.33; p ⬍0.0001) or
hypertension (OR 1.14; p ⫽ 0.0188).

Coronary Artery Disease/Aspirin Use in Atherothrombosis

449

Table 2
Aspirin dose of 18,101 United States (US) patients enrolled in the REduction of Atherothrombosis for Continued Health (REACH) Registry reporting
aspirin use at baseline
Variable
Age (years)
Age group
⬍65 years
ⱖ65 years
Gender
Male
Female
Race
White
African-American
Hispanic
Asian
Atrial fibrillation
Diabetes
Current smoking
ⱖ1 Antihypertensive agent
ⱖ1 Lipid-lowering agent
ⱖ1 Antidiabetic agent
Risk factors only
Symptomatic
Cerebrovascular disease
Coronary artery disease
Peripheral artery disease
Previous revascularization
Angiography/stent only
Coronary artery bypass
grafting only
Both
None
Region
Northeast†
Midwest‡
South§
West¶

Missing or 0 mg*
(n ⫽ 1,552)

1–74 mg
(n ⫽ 123)

75–100 mg
(n ⫽ 10,310)

101–324 mg
(n ⫽ 347)

ⱖ325 mg
(n ⫽ 5,769)

70.3 ⫾ 10.5

70.0 ⫾ 10.2

70.2 ⫾ 10.3

70.3 ⫾ 9.8

68.6 ⫾ 10.2

445 (29.1%)
1,086 (70.9%)

35 (28.9%)
86 (71.1%)

3,068 (29.9%)
7,187 (70.1%)

111 (32.1%)
235 (67.9%)

2,117 (36.9%)
3,618 (63.1%)

905 (58.5%)
642 (41.5%)

67 (54.9%)
55 (45.1%)

5,877 (57.1%)
4,419 (42.9%)

239 (68.9%)
108 (31.1%)

3,760 (65.2%)
2,004 (34.8%)

1,137 (74.5%)
214 (14.0%)
103 (6.7%)
57 (3.7%)
143 (9.4%)
784 (51.1%)
203 (13.6%)
1,471 (95.1%)
1,326 (86.4%)
734 (47.7%)
338 (22.0%)
1,197 (78.0%)
380 (25.0%)
969 (63.3%)
166 (10.7%)

93 (76.9%)
16 (13.2%)
8 (6.6%)
4 (3.3%)
11 (9.2%)
46 (37.7%)
22 (18.0%)
114 (92.7%)
101 (82.1%)
44 (35.8%)
16 (13.0%)
107 (87.0%)
67 (55.4%)
53 (43.1%)
12 (9.8%)

8,214 (80.5%)
1,019 (10.0%)
589 (5.8%)
322 (3.2%)
955 (9.5%)
5,236 (51.1%)
1,348 (13.4%)
9,697 (94.2%)
8,805 (85.8%)
4,842 (47.1%)
2,608 (25.5%)
7,632 (74.5%)
1,947 (19.2%)
6,316 (61.8%)
941 (9.1%)

311 (90.4%)
20 (5.8%)
3 (0.9%)
7 (2.0%)
34 (10.1%)
152 (44.7%)
46 (13.5%)
321 (92.5%)
301 (86.7%)
140 (40.3%)
52 (15.2%)
291 (84.8%)
68 (20.0%)
246 (71.9%)
35 (10.1%)

4,816 (84.2%)
523 (9.1%)
256 (4.5%)
100 (1.7%)
425 (7.5%)
2,668 (46.4%)
850 (15.0%)
5,435 (94.2%)
5,040 (87.6%)
2,428 (42.2%)
763 (13.3%)
4,988 (86.7%)
1,127 (19.9%)
4,289 (74.7%)
536 (9.3%)

270 (17.9%)
256 (16.9%)

13 (10.8%)
16 (13.3%)

1,971 (19.4%)
1,856 (18.2%)

78 (22.7%)
83 (24.1%)

1,555 (27.3%)
1,268 (22.3%)

164 (10.9%)
821 (53.7%)

13 (10.8%)
78 (63.9%)

929 (9.1%)
5,423 (52.9%)

43 (12.5%)
140 (40.6%)

716 (12.6%)
2,148 (37.5%)

328 (21.1%)
378 (24.4%)
579 (37.3%)
244 (15.7%)

21 (17.1%)
42 (34.1%)
40 (32.5%)
19 (15.4%)

1,849 (17.9%)
2,500 (24.2%)
3,926 (38.1%)
1,931 (18.7%)

66 (19.0%)
88 (25.4%)
118 (34.0%)
71 (20.5%)

1,112 (19.3%)
1,537 (26.6%)
2,224 (38.6%)
847 (14.7%)

Data are presented as mean ⫾ SD or numbers (%).
For each variable, percentage reflects total number of patients with available data only, not total number of patients.
* Of those who checked “yes” to baseline aspirin use, 18 put “0” as dose in mg/day and 1,534 left mg/day empty.
†
Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey, Pennsylvania.
‡
Ohio, Indiana, Illinois, Michigan, Wisconsin, Minnesota, Iowa, Missouri, North Dakota, South Dakota, Nebraska, Kansas.
§
Delaware, Maryland, District of Columbia, Virginia, West Virginia, North Carolina, South Carolina, Georgia, Florida, Kentucky, Tennessee, Alabama,
Mississippi, Arkansas, Louisiana, Oklahoma, Texas.
¶
Montana, Idaho, Wyoming, Colorado, New Mexico, Arizona, Utah, Nevada, Washington, Oregon, California, Alaska, Hawaii.

The factors associated with greater aspirin use at baseline
included a history of stent implantation, coronary artery
bypass surgery, myocardial infarction, or transient ischemic
attack; an ankle-brachial index of ⬍0.9; the use of other
secondary preventive medications, including angiotensin II
receptor blockers, biguanides, angiotensin-converting enzyme inhibitors, nitrates, ␤-blockers, statins, and other lipid-lowering agents; and white race (Figure 4).
The multivariate predictors of using low-dose vs higher
dose aspirin (Figure 4) included using oral anticoagulants
(OR 1.89; p ⬍0.0001) or antiplatelets other than aspirin
(OR 1.20; p ⬍0.0001); Asian race (OR 1.76; p ⬍0.0001);
Hispanic race (OR 1.46; p ⬍0.0001); female gender (OR
1.28; p ⬍0.0001); and hypertension (OR 1.14; p ⫽ 0.0202)
or diabetes mellitus (OR 1.11; p ⫽ 0.0038). Each additional

10 years of age was associated with a 14% greater likelihood of taking low-dose aspirin (OR 1.14; p ⬍0.0001).
For the treating physician, each additional year in medical practice was associated with a 1.2% greater likelihood of the patient taking low-dose aspirin (OR 1.012;
p ⬍0.0001). Treatment by a physician in a suburban
location (compared with an urban or a rural location) was
associated with greater use of low-dose aspirin (OR 1.14;
p ⫽ 0.0003).
The likelihood of low-dose aspirin use was lower (ie,
higher dose aspirin was used) for patients with a history of
myocardial infarction (OR 0.89; p ⫽ 0.0037), carotid
surgery (OR 0.80; p ⫽ 0.0021), ischemic stroke (OR 0.77;
p ⬍0.0001), coronary artery bypass surgery (OR 0.77;
p ⬍0.0001), or stent placement (OR 0.67; p ⬍0.0001); for
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Figure 4. Baseline predictors of (A) lack of aspirin use, (B) low-dose (75 to 100 mg/day; ⬍75 mg was omitted from analysis and ⬎100 mg was used as
referent) aspirin use, and (C) lack of antithrombotic use with 95% confidence intervals. *Included thienopyridines (clopidogrel and ticlopidine) and
dipyridamole, but not nonsteroidal anti-inflammatory drugs or cilostazol. †Included glucosidase inhibitors and meglitinides. ‡Included fibrates, bioacid resins,
niacin, and ezetimibe. §For every 10 additional years of age. ¶History of intermittent claudication associated with lower limb artery angioplasty/stenting/
bypass graft. 储For every 1 additional year in clinical practice. ABI ⫽ ankle-brachial index; ACE-I ⫽ angiotensin-converting enzyme inhibitor; A fib ⫽ atrial
fibrillation; ARB ⫽ angiotensin II receptor blocker; CABG ⫽ coronary artery bypass graft; CHF ⫽ congestive heart failure; DM ⫽ diabetes mellitus; MI ⫽
myocardial infarction; NSAIDs ⫽ nonsteroidal anti-inflammatory drugs; TIA ⫽ transient ischemic attack.

those taking ␤ blockers (OR 0.85; p ⬍0.0001); and for
those treated by a cardiologist (OR 0.73; p ⬍0.0001;
Figure 4).
Because many patients not taking aspirin were taking
other antithrombotic drugs, we evaluated the multivariate
predictors of a lack of any antithrombotic agent (Figure 4).

Patients less likely to be taking any antithrombotic agent
had diabetes mellitus (OR 1.41; p ⬍0.0001), were female
(OR 1.38; p ⬍0.0001), were current smokers (OR 1.26; p
⬍0.0001), and were taking diabetic medications other than
insulin or biguanides (OR 1.36; p ⫽ 0.0008) or nonsteroidal
anti-inflammatory drugs (OR 1.24; p ⬍0.0001).

Coronary Artery Disease/Aspirin Use in Atherothrombosis

Subjects more likely to be taking an antithrombotic agent
at baseline were white; had CAD, cerebrovascular disease,
atrial fibrillation, PAD, or previous vascular intervention;
were taking angiotensin II receptor blockers, angiotensinconverting enzyme inhibitors, nitrates, ␤-blockers, statins,
or lipid-lowering agents; or were being treated by a cardiologist (Figure 4).
Discussion
In this large registry of ⬎25,000 outpatients in the US
with documented vascular disease or multiple risk factors,
70% of those enrolled were using aspirin. The most common dose of aspirin was 75 to 100 mg/day. This widespread
use of low-dose aspirin was supported by the lack of additional clinical benefit1 and increased risk of major bleeding2
observed with higher doses. Among the aspirin nonusers,
nearly 1/2 were taking other antithrombotic agents, although approximately 15% were not using any antithrombotic therapy. The use for primary prevention was substantially lower than that for secondary prevention. Among
patients with symptomatic cardiovascular disease, 25%
were not taking aspirin. Although 63% of these aspirin
nonusers were using a different antithrombotic therapy, 9%
were taking no antithrombotic agent.
The strongest predictor of aspirin nonuse was the use of
an oral anticoagulant. This is consistent with a previous
study of patients with CAD8 and was not surprising because
concomitant use of oral anticoagulants is not necessarily
more effective and significantly increases the risk of major
bleeding.9 –11 Despite the lack of improved efficacy and
increased risk of bleeding, 6% of all patients were taking
both aspirin and warfarin. Further, 1% of patients were
taking aspirin, warfarin, and another antiplatelet agent, a
combination associated with an even greater risk of bleeding.12 Perhaps to minimize the risk of bleeding as much as
possible, the use of oral anticoagulants was a predictor of
low-dose aspirin use. Although it might be expected that the
vast majority of the combined aspirin/anticoagulant therapy
recipients would have had atrial fibrillation, this was not
observed; ⬍50% of combined therapy recipients had atrial
fibrillation. Overall, these observations suggest a gap between clinical evidence and practice that needs to be addressed.
Current evidence-based clinical practice guidelines, as
well as those current at enrollment, have recommended that
all patients with a history of CAD, cerebrovascular disease,
or PAD, as well as those with a high risk of developing
cardiovascular disease, receive aspirin or another antiplatelet therapy as protection against ischemic events. Recent
data have suggested that aspirin might not be as effective in
preventing ischemic events, suggesting future evidencebased guidelines might not be as liberal in their recommendations for aspirin use, particularly for primary prevention.
In the most recent meta-analysis of the efficacy and safety
of aspirin for the primary and secondary prevention of
vascular disease, the Antithrombotic Trialists’ Collaboration concluded that in the current era of secondary prevention, aspirin provides a net benefit for patients with established cardiovascular disease, regardless of gender.13 In
contrast, they concluded that for primary prevention, aspirin
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does not provide a net benefit, regardless of gender or
underlying disease risk. The investigators of a separate
meta-analysis concluded that aspirin used for primary prevention was beneficial in reducing the risk of myocardial
infarction in men and stroke in women, with the overall
benefit dependent on the baseline risks of cardiovascular
disease and gastrointestinal bleeding.14 Recent clinical trial
data have also shown that aspirin is not effective as primary
prevention for patients with asymptomatic PAD with or
without diabetes mellitus15,16 or as secondary prevention for
patients with type 2 diabetes mellitus17 or PAD.18 It will be
of interest to determine whether these new data will shift the
use of aspirin in primary prevention.
Our study has several limitations. Efforts were made to
recruit representative participants from the patient population of interest; however, the study population was necessarily a judgment/convenience sample, making generalization of the findings beyond the participants difficult.4,5
Although the case report form included a large number of
relevant variables, important explanatory variables (eg, certain co-morbidities, disease onset and duration, continuity,
and quality of care provided) were necessarily omitted to
allow the feasibility of this large study and minimize attrition. The patients’ history of bleeding events was not collected
at baseline. During follow-up, the only bleeding-related variables assessed were the occurrence of hemorrhagic stroke or an
episode of bleeding that led to hospitalization and blood transfusion. Specific information about patient adherence was not
recorded, suggesting the results might have overestimated the
true use of aspirin. Information about the preparation of aspirin
(eg, enteric-coated, chewable) and any contraindications to
aspirin in aspirin nonusers were not recorded.
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